Gossamer Bio, Inc. last reported quarterly results on Jul 27, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $9.2 million (-19.6% year over year) and diluted EPS of -$0.08. It usually reports 27–48 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 4, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Nov 5, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 27–48 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Jul 27, 2026
27 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
9
-19.6%
|
17
+144.2%
|
-0.08
+52.9%
|
|
May 18, 2026
48 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
17
+71.5%
|
-47
-27.4%
|
-0.20
-25.0%
|
|
Nov 5, 2025
36 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
13
+40.2%
|
-48
-56.5%
|
-0.21
-50.0%
|
|
Aug 5, 2025
36 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
11
-88.0%
|
-38
-177.7%
|
-0.17
-177.3%
|
|
May 15, 2025
45 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
10
|
-37
+12.6%
|
-0.16
+15.8%
|
|
Mar 13, 2025
72 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
9
|
-33
+31.4%
|
-0.15
+31.8%
|
|
Nov 7, 2024
38 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
9
|
-31
+23.0%
|
-0.14
+33.3%
|
|
Aug 12, 2024
43 days after quarter end
|
—
ended Jun 30, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GOSS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1728117
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.